Integra LifeSciences (NASDAQ:IART) Stock Gets Price Target Reduction from JPMorgan Chase & Co.

Integra LifeSciences (NASDAQ:IART) had its target price cut by JPMorgan Chase & Co. from $17.00 to $14.00 in a report published on Thursday morning,Benzinga reports. They currently have an underweight rating on the life sciences company’s stock.

IART has been the topic of a number of other research reports. UBS Group began coverage on shares of Integra LifeSciences in a research note on Tuesday, July 28th. They issued a “neutral” rating and a $19.00 price target on the stock. BMO Capital Markets cut their price objective on shares of Integra LifeSciences from $18.00 to $15.00 and set a “market perform” rating for the company in a research report on Monday, October 5th. Wells Fargo & Company set a $13.00 price objective on Integra LifeSciences and gave the stock an “equal weight” rating in a report on Thursday. Weiss Ratings cut Integra LifeSciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 2nd. Finally, Truist Financial decreased their target price on Integra LifeSciences from $19.00 to $15.00 and set a “hold” rating on the stock in a research report on Wednesday, October 14th. Two analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $16.75.

Integra LifeSciences Price Performance

Shares of IART opened at $11.91 on Thursday. The company has a market cap of $926.24 million, a price-to-earnings ratio of 70.06, a PEG ratio of 0.64 and a beta of 1.21. Integra LifeSciences has a 1-year low of $8.70 and a 1-year high of $20.49. The company’s fifty day simple moving average is $15.31 and its 200 day simple moving average is $15.56. The company has a current ratio of 3.60, a quick ratio of 2.11 and a debt-to-equity ratio of 1.75.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Wednesday, October 21st. The life sciences company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.56 by $0.03. The firm had revenue of $411.18 million during the quarter, compared to analysts’ expectations of $413.16 million. Integra LifeSciences had a net margin of 0.79% and a return on equity of 18.74%. During the same quarter last year, the company posted ($0.07) earnings per share. On average, research analysts forecast that Integra LifeSciences will post 2.34 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in IART. Paradigm Capital Management Inc. NY acquired a new stake in shares of Integra LifeSciences in the second quarter valued at approximately $61,766,000. Wellington Management Group LLP increased its stake in Integra LifeSciences by 12.4% during the 2nd quarter. Wellington Management Group LLP now owns 1,461,104 shares of the life sciences company’s stock worth $26,241,000 after acquiring an additional 160,814 shares during the period. Bank of America Corp DE increased its stake in Integra LifeSciences by 71.4% during the 1st quarter. Bank of America Corp DE now owns 1,414,509 shares of the life sciences company’s stock worth $13,325,000 after acquiring an additional 589,408 shares during the period. Glenmede Trust Co. NA increased its stake in Integra LifeSciences by 27.4% during the 1st quarter. Glenmede Trust Co. NA now owns 984,686 shares of the life sciences company’s stock worth $9,276,000 after acquiring an additional 211,774 shares during the period. Finally, Access Investment Management LLC raised its holdings in Integra LifeSciences by 39.5% in the 3rd quarter. Access Investment Management LLC now owns 564,982 shares of the life sciences company’s stock valued at $9,198,000 after acquiring an additional 159,980 shares in the last quarter. Institutional investors and hedge funds own 84.78% of the company’s stock.

Key Headlines Impacting Integra LifeSciences

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Integra’s third-quarter EPS beat analysts’ expectations, offering some support to the investment case despite the revenue shortfall. Integra Q3 2026 Earnings Call Transcript
• Positive Sentiment: Some analysts continue to see substantial upside if restructuring gains traction, product relaunches succeed and market conditions normalize. Citizens JMP maintained a “market outperform” rating, although it reduced its price target to $22 from $25. Citizens JMP Price Target
• Positive Sentiment: The stock’s depressed valuation could attract value-oriented investors if Integra can restore margins and cash-flow growth; one analysis expects EBITDA margins above 20% and potentially double-digit free-cash-flow margins over time. Integra LifeSciences Valuation Analysis
• Neutral Sentiment: Integra completed a $2.1 billion refinancing, but its revolving credit commitment declined by $700 million to $600 million. The transaction addresses near-term financing needs while highlighting investor concerns about leverage and financial flexibility. Integra Refinancing Analysis
• Negative Sentiment: Analysts broadly lowered their expectations: Truist cut its price target to $13 from $15 and kept a “hold” rating; Citigroup reduced its target to $14 and maintained “neutral”; and JPMorgan lowered its target to $14 from $17 while retaining an “underweight” rating. Truist Price Target
• Negative Sentiment: Investors remain concerned about flooding-related disruption, specialty surgical headwinds, tissue reconstruction weakness and refinancing risk, all of which could delay the turnaround and pressure future earnings. Integra Q3 Revenue Miss
• Negative Sentiment: Multiple law firms announced investigations into potential securities-law violations related to Integra’s disclosures, adding legal and reputational uncertainty, although no wrongdoing has been established. Integra Securities Investigation

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, orthopedics and wound care. Its portfolio includes medical devices, surgical instruments and regenerative tissue technologies designed to help healthcare professionals treat complex conditions and support patient recovery.

Integra’s neurosurgical products include dural repair products, cerebrospinal fluid management systems, cranial stabilization devices and specialized surgical instruments.